SCHEDULE: FMR LLC Amends Moonlake Immunotherapeutics Stake

FMR LLC and Abigail P. Johnson have filed an Amendment No. 4 to their Schedule 13G, reporting a 1.1% beneficial ownership in Moonlake Immunotherapeutics' Class A Common Stock as of September 30, 2025.

Summary

• FMR LLC and Abigail P. Johnson filed an Amendment No. 4 to their Schedule 13G regarding their beneficial ownership in Moonlake Immunotherapeutics.
• The filing reports beneficial ownership of 726,931.33 shares of Moonlake Immunotherapeutics' Class A Common Stock.
• This ownership represents 1.1% of the total outstanding Class A Common Stock.
• The event requiring this filing occurred on September 30, 2025.
• FMR LLC, a Delaware-organized parent holding company, holds sole voting power over 724,891.70 shares and sole dispositive power over 726,931.33 shares.
• Abigail P. Johnson, a U.S. citizen, holds sole dispositive power over 726,931.33 shares.
• Abigail P. Johnson is identified as a Director, Chairman, and Chief Executive Officer of FMR LLC, and a predominant owner of FMR LLC through the Johnson family's Series B voting common shares.
• The filing includes a Rule 13d-1(k)(1) agreement for joint filing by FMR LLC and Abigail P. Johnson.

Sentiment

Score: 5

Explanation: The filing is a neutral, factual disclosure of beneficial ownership. It does not contain information that would inherently drive a strong positive or negative sentiment regarding the issuer's performance, though institutional ownership can be seen as a minor positive signal.

Positives

• Continued institutional ownership by FMR LLC, a major financial services firm, may signal confidence in Moonlake Immunotherapeutics.
• The disclosure of a 1.1% stake by a prominent investment group like FMR LLC can enhance market visibility and potentially attract other institutional investors.

Negatives

• The filing itself does not contain negative information about Moonlake Immunotherapeutics; it is a disclosure of ownership.
• Without prior filings, it is unclear if this 1.1% represents an increase or decrease in ownership, which would be the only potential 'negative' if it were a significant reduction.

Risks

• The filing does not detail specific risks related to Moonlake Immunotherapeutics' operations or financial health; it is solely an ownership disclosure.

Future Outlook

The filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding Moonlake Immunotherapeutics' future performance or FMR LLC's investment strategy.

Management Comments

• The filing does not contain direct quotes or paraphrased statements from Moonlake Immunotherapeutics' management. It includes certifications from Stephanie J. Brown, duly authorized under Power of Attorney for FMR LLC and Abigail P. Johnson, stating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Industry Context

This Schedule 13G filing reflects a routine disclosure by a major institutional investor, FMR LLC (Fidelity), regarding its passive stake in Moonlake Immunotherapeutics. Such filings are common in the financial industry, providing transparency on significant ownership positions. The presence of a large, well-known asset manager like FMR LLC on a company's shareholder list can sometimes be viewed positively by the market, suggesting a level of due diligence and confidence in the issuer, particularly for a company in the biotechnology or pharmaceutical sector (implied by 'Immunotherapeutics').

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which could be viewed as a positive signal of confidence.
• Investment Professionals: Offers updated data on institutional ownership, which is a key data point for market analysis.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for Moonlake Immunotherapeutics or FMR LLC's investment strategy beyond the routine nature of such disclosures.

Key Dates

Keywords

Moonlake Immunotherapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, Class A Common Stock, institutional investor, SEC filing, equity stake